NCT06614140 2026-04-22
Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors
Seqker Biosciences, Inc.
Phase 1/2 Completed
Clinical Trials
3 trialsNCT01079741 2018-02-13
Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT02661100 2016-12-07
A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
Case Comprehensive Cancer Center
Phase 1/2 Withdrawn